Understanding that there were serious financial ramifications to its bottom line as a result of the AIDS epidemic, Anglo-American sought to provide free antiviral therapy to members of its South African workforce who were infected with the HIV/ AIDS. Despite the many positives associated with this decision, Anglo-Americans’ attempt to stem the ramifications of the HIV AIDS epidemic was met with resistance and unsure results. As a result, Anglo-American halted its pilot study. The following explores the reasons for Anglo-Americans decision to halt this landmark study and are they reasonable? What recommendations would an educated reader give Anglo-American with respect to its HIV/AIDS policy? Seem to address these questions and many more, the following will explore Anglo-American and the challenges it faces tackling the HIV/AIDS epidemic in South Africa.
Anglo-American is an international organization with roots in South Africa and as a multinational company is one of the largest employers in the country. Today, Anglo-American has 80,000 employees nation-wide and has been significantly affected by the global AIDS epidemic. The global HIV/AIDS outbreak began in the 1980s and Anglo-American was one of the first multinational corporations to understand and attempt to combat the ramifications of this insidious disease. Accordingly, South Africa remains the country with one of the highest infection rates in the world and corporations like Anglo-American quickly understood that this disease had the potential to significantly affect the bottom line of its company. With much invested in the South African state, Anglo-American sought to address the HIV/AIDS epidemic in the early 1980s and a landmark decision in 2002 to provide free antiviral medicine to its infected workforce represented a further evolution of the enlightened policies of companies like